Personal information

No personal information available

Activities

Collapse all

Employment (3)

American Society of Clinical Oncology: Alexandria, VA, US

2021-02-15 to present | Chief Medical Officer
Employment
Source: Self-asserted source
Julie Gralow

University of Washington: Seattle, WA, US

1992-07-01 to 2021-02-05 | Professor (Medicine/Oncology)
Employment
Source: Self-asserted source
Julie Gralow

Fred Hutchinson Cancer Research Center: Seattle, WA, US

1992-07-01 to 2021-02-05 | Professor (Clinical Research)
Employment
Source: Self-asserted source
Julie Gralow

Works (28)

Differential Survival Among Patients With Cancer by COVID-19 Vaccination Status: An Analysis of the ASCO COVID-19 Registry

JCO Oncology Advances
2024-11 | Journal article
DOI: 10.1200/OA-24-00034
Contributors: M. Kelsey Kirkwood; Charu Aggarwal; Suanna S. Bruinooge; Jen Hanley Williams; Melinda Kaltenbaugh; Natalie Ramos; Julie R. Gralow; Elizabeth Garrett-Mayer
Source: check_circle
Crossref

Impact of Medical Oncology–Focused Quality Programs on Cancer Care Around the World

American Society of Clinical Oncology Educational Book
2024-06 | Journal article
DOI: 10.1200/EDBK_432102
Contributors: Deirdre O’Mahony; Carlos Frederico Pinto; Jackson Orem; Megan Mcleod; Ajay Aggarwal; Julie R. Gralow
Source: check_circle
Crossref

Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226

Pharmacogenomics
2023-08 | Journal article
DOI: 10.2217/pgs-2023-0097
Contributors: Delaney V Rutherford; Sarah Medley; Nicholas C Henderson; Christina L Gersch; Ted A Vandenberg; Kathy S Albain; Shaker R Dakhil; Nagendra R Tirumali; Julie R Gralow; Gabriel N Hortobagyi et al.
Source: check_circle
Crossref

Data from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532601
Contributors: Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy et al.
Source: check_circle
Crossref

Data from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532601.v1
Contributors: Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy et al.
Source: check_circle
Crossref

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530384
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Data from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530384.v1
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Figure S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480175
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Figure S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480175.v1
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Figure S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480172
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Figure S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480172.v1
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487873
Contributors: Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy et al.
Source: check_circle
Crossref

Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487873.v1
Contributors: Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy et al.
Source: check_circle
Crossref

Table S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480169
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Table S1 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480169.v1
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Table S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480166
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

Table S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480166.v1
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

Clinical Cancer Research
2022-02-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-3131
Contributors: Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy et al.
Source: check_circle
Crossref

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

Journal of Clinical Oncology
2022-02-10 | Journal article
DOI: 10.1200/JCO.21.00896
Contributors: Ian E. Krop; Seock-Ah Im; Carlos Barrios; Hervé Bonnefoi; Julie Gralow; Masakazu Toi; Paul A. Ellis; Luca Gianni; Sandra M. Swain; Young-Hyuck Im et al.
Source: check_circle
Crossref

Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Women’s Empowerment Cancer Advocacy Network (WE CAN) Summits

JCO Global Oncology
2021-12 | Journal article
DOI: 10.1200/GO.20.00532
Contributors: Nicoleta Antone; Darya Kizub; Julie Gralow; Jo Anne Zujewski; Allison Dvaladze
Source: check_circle
Crossref

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

Journal of Clinical Oncology
2021-12-10 | Journal article
DOI: 10.1200/JCO.21.01374
Contributors: Beverly Moy; R. Bryan Rumble; Steven E. Come; Nancy E. Davidson; Angelo Di Leo; Julie R. Gralow; Gabriel N. Hortobagyi; Douglas Yee; Ian E. Smith; Mariana Chavez-MacGregor et al.
Source: check_circle
Crossref

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Clinical Cancer Research
2021-11-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-1562
Contributors: Costanza Paoletti; William E. Barlow; Erin F. Cobain; Mattias Bergqvist; Rita S. Mehta; Julie R. Gralow; Gabriel N. Hortobagyi; Kathy S. Albain; Lajos Pusztai; Priyanka Sharma et al.
Source: check_circle
Crossref

The Global Landscape of Treatment Standards for Breast Cancer

JNCI: Journal of the National Cancer Institute
2021-09-04 | Journal article
DOI: 10.1093/jnci/djab011
Contributors: Dario Trapani; Jean Yves Douillard; Eric P Winer; Harold Burstein; Lisa Anne Carey; Javier Cortes; Gilberto Lopes; Julie R Gralow; William J Gradishar; Nicola Magrini et al.
Source: check_circle
Crossref

Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors

JNCI: Journal of the National Cancer Institute
2021-08-02 | Journal article
DOI: 10.1093/jnci/djab022
Contributors: Dawn L Hershman; Alfred I Neugut; Anna Moseley; Kathryn B Arnold; Julie R Gralow; N Lynn Henry; Grace Clarke Hillyer; Scott D Ramsey; Joseph M Unger
Source: check_circle
Crossref

Time to Focus on Breast Cancer in Young Adults

JCO Oncology Practice
2021-06 | Journal article
DOI: 10.1200/OP.20.01060
Contributors: Rachel L. Yung; Julie R. Gralow
Source: check_circle
Crossref

When cardiomyopathy, cancer, and COVID‐19 collide: A case report

The Breast Journal
2021-04 | Journal article
DOI: 10.1111/tbj.14182
Contributors: Lynn Symonds; Poorna Natarajan; Richard K. Cheng; Diana L. Lam; Mark Kilgore; Janice Kim; Kristine Calhoun; Elina Minami; Julie R. Gralow
Source: check_circle
Crossref

Recommendations from the ASCO Academic Global Oncology Task Force

JCO Global Oncology
2020-11 | Journal article
DOI: 10.1200/GO.20.00497
Contributors: Julie R. Gralow; Fredrick Chite Asirwa; Ami Siddharth Bhatt; Maria T. Bourlon; Quyen Chu; Alexandru E. Eniu; Patrick J. Loehrer; Gilberto Lopes; Lawrence N. Shulman; Julia Close et al.
Source: check_circle
Crossref

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

JNCI: Journal of the National Cancer Institute
2020-07-01 | Journal article
DOI: 10.1093/jnci/djz215
Contributors: Julie R Gralow; William E Barlow; Alexander H G Paterson; Jieling L M'iao; Danika L Lew; Alison T Stopeck; Daniel F Hayes; Dawn L Hershman; Mark M Schubert; Mark Clemons et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for The Breast. (1)
How many people are using ORCID?